Differentiation strategies for the generic industrry
-
Upload
asacox -
Category
Healthcare
-
view
178 -
download
0
description
Transcript of Differentiation strategies for the generic industrry
![Page 1: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/1.jpg)
Differentiation Strategiesfor the Generic Industry
Biosimilar Drug Development WorldBoston, Tues 19th Nov 2013
![Page 2: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/2.jpg)
The PlanSession 1: IntroductionWelcome, Who?!, Why?Current differentiation strategies
Session 2: ChallengesProduct, Organisation, Intimacy, Execution
Session 3: IdeasProduct, Organisation, Intimacy, Idea Factory
Session 4: The FutureTrends, Insights, Expectations
![Page 3: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/3.jpg)
Fujifilm Kyowa Kirin BiologicsGreenstoneLaboratorios EcarPfizerPharmascience
WelcomeWho are you?
AbbottAlfred E.TiefenbacherAvannlab - MedicusBoehringer IngelheimCapsugelEva Pharma
![Page 4: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/4.jpg)
WelcomeWho am I?Founder Generic Pharma 2.016 years in Gx:6 years Packaging, API, C/M8 years Business Development & Licensing2 years market intelligence & global consulting
Imagineering: Insights, ideas, strategy
Have done ‘something’ with:- Pfizer & Greenstone- Boehringer Ingelheim- Pharmascience
![Page 5: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/5.jpg)
WelcomeWho am I?
![Page 6: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/6.jpg)
![Page 7: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/7.jpg)
WelcomeWhy are we here?- Future of the industry is very different from today- Growth markets are “easier said than done”- Biosimilars will be branded, few have sufficient capital- Competition in small molecule never ends- Government funding and policies fluctuate- MNC’s into generics, generics into speciality pharma, speciality into OTC
The challenge:
Where should time be spent and investment be made?
![Page 8: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/8.jpg)
WelcomeWhy are we here?To discuss DIFFERENTIATION:- The process or action of being different (duh!)- To show a difference that distinguishes
To discuss STRATEGIES for it:“The intelligent allocation of limited resources through a unique system of activities to outperform the competition in serving customers”
Why is this workshop needed?Companies in the generic pharma industry (generally)...Underinvest & focus on alternative strategies for competitive advantage
![Page 9: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/9.jpg)
WelcomeWhy are we here?
To be better than the competition!Competitive exclusion principle:
“No two members of the same species can coexist that make their livings in the identical way”
![Page 10: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/10.jpg)
Competitive AdvantageDefined:
“An offering of superior value based on differences in capabilities and activities”
Three components:
- Distinctive Capabilities: Resources + Competencies
- Investment in Activities: Optimisation + Co-ordination (value chain)
- Market Offerings: Consistent positive difference + Credibility/Trust
![Page 11: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/11.jpg)
Competitive AdvantageTransformation Options:1) Better alignment between offering and capabilities
2) Create new capabilities
3) Influence customer preference
4) Change the game - innovate to create a space without competition
![Page 12: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/12.jpg)
Competitive AdvantageBusiness Value Options:
- Product Leadership- Operational Excellence- Customer Intimacy
Alternative to singular focus
MEDIOCRITY & COMMODITISATION
Need to be either; better or different.. we will focus on different
![Page 13: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/13.jpg)
Competitive AdvantageThe problem (status quo)Product Leadership:Generic drugs by definition are commoditiesPatent expiries determine portfolio and drive growthSignificant market share is gained by being the lowest cost
Operational Excellence:Focus on manufacturing & supply chain (to lower costs)Regulatory & legal are the tools to unlock new revenue
Customer Intimacy:A generic company cannot influence (end) consumer preference or intimacyThe trade customer shows loyalty only to price
![Page 14: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/14.jpg)
Competitive AdvantageThe AnswerYou, me and this workshop!
![Page 15: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/15.jpg)
Current StrategiesWhat is happening out there?
Is anyone actually differentiating in generic pharma right now…
PiSA - MexicoDenver Pharma - ArgentinaBiocad - RussiaHelp Remedies - USAAbbott / Piramal - USA / IndiaAlvogen - Iceland / USA
You decide.
![Page 16: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/16.jpg)
Current StrategiesWhat is happening out there?PiSA Farmaceutica - Mexico
Operations: Manufacturing Excellence- Solid Orals - Injections - Infusions
Product: All categories- Nutrition - OTC - Gx Retail - Gx Hospital - Biosimilar
Intimacy: Key services- Low income pharmacies next to hospitals- In-house logistics & distribution centres- Dialysis Centres
![Page 17: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/17.jpg)
Current StrategiesWhat is happening out there?PiSA Farmaceutica - Mexico
Which one is strongest differentiator?
Success:- No1 domestic Pharma in Mexico- $500m revenue (estimated, private company)- Defended against MNC’s & international generics- Operations across region, export 2million med devices to USA
Competitive Strategy:- Full integration, 360 healthcare provision
![Page 18: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/18.jpg)
Current StrategiesWhat is happening out there?Product, Operations, Intimacy
Denver Farma - Argentina
Operations: Nothing special. Solid oral, liquid, semi-solidProduct: Gx Retail, some OTC
Intimacy: Promotion- Large pharmacy sales team- Mass media consumer advertising
Success: 40% annual growth, moving up 20 ranking places in 3 years
![Page 19: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/19.jpg)
Current StrategiesWhat is happening out there?Biocad - Russia
Operations: Biotech Focus- Technical leaders in biotech production
Product: Disease focus- Viral infections; developed novel formulations of Interferon- International partnerships on disease area
Intimacy: KOLs- Strong connections with hospitals and clinicians (and government!)
Success: Founded 2001, 1st product 2005, 2014 sale likely $750m-$1bn
![Page 20: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/20.jpg)
Current StrategiesWhat is happening out there?Help Remedies - USA [HelpINeedHelp.com]
![Page 21: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/21.jpg)
Current StrategiesWhat is happening out there?Help Remedies - USA
![Page 22: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/22.jpg)
Current StrategiesWhat is happening out there?Help Remedies - USA
Operations: No manufacturing, No regulatory. Just marketing.
Product: Design, Branding, Message
Intimacy: As close as possible! [Video]
Success: Launched 2008 300million visitors, international awards Stocked by hotels, major pharmacies, national retailers Recently acquired for undisclosed amount Next stop, international growth
![Page 23: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/23.jpg)
Current StrategiesWhat is happening out there?Abbott (Piramal) - India- Acquired Piramal for sales force- Historic Indian family name (vs Abbott 1910)- Low cost manufacturing capabilities
Corporate Social Responsibility activities- Health information phone lines and telemedicine- Mobile health units for those beyond 3km from centre (400k treated)- e-Swasthya; provide training & cell phone to local women, connected to diagnosis call centre- Government nutrition partnership, enhanced rice (500k people helped)
![Page 24: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/24.jpg)
Current StrategiesWhat is happening out there?Abbott (Piramal) - India
Product: Global brands & locally developed products
Operations: Local manufacturing. Massive distribution. Deep rural access.
Intimacy: Focus on Corporate Social Responsibility; builds deep trust
Success: Biggest & fastest growing pharma in India
![Page 25: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/25.jpg)
Current StrategiesWhat is happening out there?Alvogen - USA
![Page 26: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/26.jpg)
Current StrategiesAlvogen Inc - USA
![Page 27: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/27.jpg)
Current StrategiesAlvogen Inc - USA
![Page 28: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/28.jpg)
Current StrategiesAlvogen Inc - USA
![Page 29: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/29.jpg)
Current StrategiesAlvogen Inc - USA
![Page 30: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/30.jpg)
Current StrategiesWhat is happening out there?Alvogen - USA
Product: ‘hard to make’ and first-to-file Gx, OTC, Biosimilar (coming)
Operations: Lean & quick. Pharmerging focus + USA (50/50 revenue)
Intimacy: Engaging marketing; Corporate brand for OTC
Success: Profitable. Acquiring (big deals in 2012), aiming for Top 10
![Page 31: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/31.jpg)
Current StrategiesWhat is your company value strategy?- Product Leadership- Operational Excellence- Customer Intimacy
AbbottAlfred E.TiefenbacherAvannlab - MedicusBoehringer IngelheimCapsugelEva Pharma
What about industry ‘leaders’?
- Teva- Mylan- Watson- Sandoz- Hospira- Amneal
Fujifilm Kyowa Kirin GreenstoneLaboratorios EcarPfizerPharmascience
![Page 32: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/32.jpg)
Session 2: Challenges
![Page 33: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/33.jpg)
My ambition
![Page 34: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/34.jpg)
My ability
![Page 35: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/35.jpg)
ChallengesBe better, not just different
Internal Challenges - Investment: growth stage, ownership, control - Human resources: talent, expertise, desire- Management: risk tolerance, vision, commitment - Shareholders: time horizon, understanding, vision
External Challenges- Competitive market forces- Government policy- Availability of resources (data, expertise, finance)
![Page 36: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/36.jpg)
ChallengesWhat is required?
- Expertise - Insights - Resources (internal & external )- Time
ProductOperations
Intimacy
![Page 37: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/37.jpg)
ChallengesProduct
Resources - Manufacturing- R&D- Distribution - Market access
Expertise - Regulatory- Legal & IP - Marketing
Insights - Selection criteria / strategy - Market intelligence (competition plans)- Future needs of the buyer - Disease data
Time - Evolution vs radical - Type: small, biotech, otc - Type: formulation, delivery, packaging,
![Page 38: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/38.jpg)
ChallengesOperations
Expertise- Efficiency - Product Development - Resource management - Project management - Partnership and collaboration
Insights - Effective communication - Future of the effective organization - Market intelligence - Future of manufacturing - In house vs out source
Resources - Partner network - Collaboration tools - Communication tools - Management information systems
Time - Organic vs inorganic - Gap analysis - Current culture- Management effectiveness
![Page 39: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/39.jpg)
ChallengesIntimacy
Expertise - Relationship building- Market research - Data analysis/interpretation- Marketing and branding - Product adaptation
Insights - Future needs of buyers- Market nuances- Government and industry policy (payment, availability, cost, category etc )
Resources - Marketing services- Access to customers- Integrated organization
Time - Investment- Credibility- Readiness of organization- Access to customers
![Page 40: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/40.jpg)
ChallengesThe Big Challenge
- Where to get ideas from- How to buy or build them- How to 'on board' them within resistant org.- How to improve likelihood of success
How to dissolve/modify/overhaul status quo of current organisation?!
Give the past and present, does your company have the ‘make up’ to succeed
![Page 41: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/41.jpg)
Session 3: Ideas
![Page 42: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/42.jpg)
IdeasRealistic Differentiation Potential
Within realms of possibility. Short, medium, longBetter, not just different Likely competitive advantage
![Page 43: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/43.jpg)
IdeasKey attributes for a successful Gx company:
- Selection of new products- Delivery of products- Profitable production of - Partnerships- Regulator and payor relations - Access new markets for growth
![Page 44: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/44.jpg)
IdeasDifferentiation for a successful Gx company:
- Product Leadership- Operations Excellence- Customer Intimacy
![Page 45: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/45.jpg)
ProductProduct Leadership
Focus areas for potential competitive advantage through differentiation.
Having better products
![Page 46: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/46.jpg)
ProductDose Management/Compliance- Data collection: Home dispensing recorders- Monitoring: Patient communication systems/service- Intelligent Packaging: Dose regimen notifications- Reminders: Integrated with MHR, insurance, pharmacies- Dispensing systems: Multi-drug machines- Education: Content systems to reduce intentional non-adherence- Labels: Clarity, Weight/dose information
![Page 47: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/47.jpg)
ProductSafety- Child & Geriatric best practice: pack design, readability- Anti-counterfeiting: digital verification, hologram- Dose form: stamps, coating, colour, taste- Dosing: Part doses (also patient cost reduction)- Abuse deterrents: Non-crushable, irritants, antidote combo, bio-activated
![Page 48: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/48.jpg)
ProductFirst to market- Orphan drugs: new indication for old molecule (<clinical + >safety)
- Patent challenges: salts, alternative formulations (505b2), invalidity(Finances - litigation funding, at-risk launch insurance)
- Reformulation: SR/ER, Pegylation/Liposomes, >stability (global req.), bioavailability (reduce volume), fast acting (ODT, thinstrip), solid to liquid, semi-solid to patch/tape, phase release (early morning, mid sleep etc)
"Is it valuable to the patient, valuable to the physician or valuable to the health providers/insurance companies"
![Page 49: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/49.jpg)
ProductPatient Centric- Convenience: Films, liquids, unit dose, direct-to-mouth, patch/tape Regimen/patient packs (blisters vs bottles)
- Preference: Foam or spray vs cream/gel/ointment Size - "bigger is better" vs easy-to-swallow
![Page 50: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/50.jpg)
OperationsOperations Excellence
Focus areas for potential competitive advantage through differentiation.
Having better operations.
![Page 51: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/51.jpg)
OperationsOperations Excellence
![Page 52: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/52.jpg)
OperationsR&D
- Special forces DARPA model for innovation- Optimisation (market vs manufacturing vs resources vs strategy)- Venture capital/Darwinian view of project approval
Manufacturing- Complexity/variant management:- Local 'manufacturing for local markets', regional CMO's- Continuous manufacturing (2 sites worldwide)- Manufacturing techniques e.g Foam (vs wet) granulation
![Page 53: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/53.jpg)
OperationsSourcing/Supply-Chain/Procurement
- Market intelligence via in-market sourcing offices- API R&D price reduction exchange for royalty (subject to timetable, patents etc)- Co-development (cost/profit sharing) for higher risk (competition, time, costs, reg.)- Co-invention projects for global exploitation- Global benchmarking ('local' price = future regulated price)- Sourcing/purchasing plaforms, e.g io-pharma.com
![Page 54: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/54.jpg)
OperationsServices- First to market, support 'early' launch (patent breaking) with legal services- Anti-counterfeiting 'services'- Pharmacy education (product reformulation, value add etc)- Information for pharmacies (availability, new products, patents, promotions)
Outbound Logistics- Dis-intermediation (direct to pharmacy + support contract flexible buyers)- Online pharmacy (direct to patient)
![Page 55: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/55.jpg)
OperationsTechnology- Monitoring and analysis of firm-wide data:
- Decision making- Insights- Quality- Communication
- Connection of data between partners and customers- Help suppliers and buyers to improve their business- Build integrated networks with seemless data
![Page 56: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/56.jpg)
OperationsHuman Resources- Create the Google of Pharma, somewhere people want to work- CA by attracting the brightest and best in the industry (and outside)- An investor in people (vs assets)
Infrastructure- Flat, no-boss organisation like Valve Software
- Compensation based on ranking- Select projects to work on
- Knowledge factories vs labour factories
![Page 57: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/57.jpg)
IntimacyCustomer Intimacy
Focus areas for potential competitive advantage through differentiation.
Having better customer intimacy.
![Page 58: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/58.jpg)
IntimacyWho is the customer?
Next buyer in chain or end consumer?Business-to-business vs business-to-consumer
● Wholesaler / Distributor / Exporter● Payor: Insurance or Government● Pharmacy / Hospital / Website● Patient / Carer
![Page 59: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/59.jpg)
IntimacyWholesaler / Distributor / Exporter
- Market intelligence sharing (data)- Product education materials for next in chain- NPD projects for sub-sector- Rewards program
![Page 60: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/60.jpg)
IntimacyPayor: Insurance or Government
- Demonstrative superiority- Quality (preventative systems)- Reliability (stock committment)- Efficacy (significant enough?)- Compliance (very significant)
- Services- Infusion centres- Payment/reimbursement systems
![Page 61: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/61.jpg)
IntimacyPharmacy / Hospital / Website
- Patient education programs (in-store devices)- Transparency of supply chain for deliveries (data)- Legal and regulatory updates (data)- NPD ideas driven by clinicians and pharmacists- Drug management services/software- Outsourced service provision (?)
![Page 62: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/62.jpg)
IntimacyPatient / Carer
- Mobile apps for disease management (trust)- Compliance and safety programs/systems (caring)- Full disclosure of supply chain information (honesty)- Disease management portfolio discount/co-pay
Corporate Social Responsibility projects
![Page 63: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/63.jpg)
IdeasHow will you pick the best one?
- Theory vs reality- Investment analysis- Timelines
What does an idea factory for generic pharma look like?
![Page 64: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/64.jpg)
Session 4: The Future
![Page 65: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/65.jpg)
The FuturePharmagineering
What might affect the generic drug industry in 10 years?What is beyond emerging markets?What is beyond large molecule generics?
What does it mean for us today?
![Page 66: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/66.jpg)
Asa’s 2030 Futurist Thoughts
Generic drugs will be marginalised in majority of marketsOnly handful of broad portfolio playersHandful of highly specialist technology driven companiesGovernment and insurance fully integrated
Data rulesSupply chains are shortPatients order their own drugs
The Future
![Page 67: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/67.jpg)
The FuturePrevention
![Page 68: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/68.jpg)
The FuturePreventionLifestyle diseases get lifestyle treatmentExercise & diet connected to insurance & healthcarePush responsibility to population, incentives for health (tax)
![Page 69: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/69.jpg)
The FuturePersonal
Genome based healthcare managementLife diagnostics, real-time care and treatmentCradle to grave relationship with Pharma
![Page 70: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/70.jpg)
![Page 71: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/71.jpg)
The FutureTechnology
Mhealth: Smartphones, tablets & apps Data integration: manufacturing to bar codeOpen source platformsOnline drug fulfilment
![Page 72: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/72.jpg)
![Page 73: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/73.jpg)
![Page 74: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/74.jpg)
The Future‘Intelligent’ Patients
Informed choice of drug providerA relationship with drug provider demandedEthics, manufacturing data, quality reports, clinical dataDrug interactions, side affects, diet, exercise
![Page 75: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/75.jpg)
![Page 76: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/76.jpg)
The FutureThoughts & Discussion
What does the future hold?How will it affect the generic pharma industry?What competencies will be required to succeed?What can be done NOW to improve likely success?
![Page 77: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/77.jpg)
The FutureTrends/insights
- Self care- Personalised medicine & diagnostics- Technology facilitation - Connectivity and collaboration - Social responsibility - Environmental conscience- Globalized mobilized workforce - Income disparity & fiscal responsibility
- Gender roles and activities - Protectionist/self reliant government- Role of Dr, Pharmacy and Hospital - Aging population - Generation differences - Southern hemisphere power houses - Funding models (crowd/networked)
What do you see?
![Page 78: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/78.jpg)
The SummarySession 1: IntroductionWelcome, Who?!, Why?Current differentiation strategies
Session 2: ChallengesProduct, Organisation, Intimacy, Execution
Session 3: IdeasProduct, Organisation, Intimacy, Idea Factory
Session 4: The FutureTrends, Insights, Expectations
![Page 79: Differentiation strategies for the generic industrry](https://reader034.fdocuments.net/reader034/viewer/2022051817/5479cf255906b5fd348b4608/html5/thumbnails/79.jpg)
Differentiation Strategiesfor the Generic Industry
Biosimilar Drug Development WorldBoston, Tues 19th Nov 2013